• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Greenhill & Co. Reports Second Quarter 2023 Results

    8/9/23 4:05:00 PM ET
    $GHL
    Investment Bankers/Brokers/Service
    Finance
    Get the next $GHL alert in real time by email
    • Announced definitive agreement for Greenhill to be acquired by Mizuho Financial Group, Inc. in an all-cash transaction at $15 per share
    • Quarterly revenues of $71.4 million, up 98% from prior year's second quarter
    • Year to date revenues of $121.1 million, up 49% from the same period in 2022
    • Compensation ratio of 54% for the quarter; 82% for the year to date period
    • Operating margin of 21% for the quarter
    • Recruited two additional Managing Directors during the quarter

    Greenhill & Co., Inc. (NYSE:GHL) today reported revenues of $71.4 million, net income of $4.4 million and diluted earnings per share of $0.21 for the quarter ended June 30, 2023.

    The Firm's second quarter 2023 revenues compare to revenues of $36.0 million in the second quarter of 2022, which represents an increase of $35.4 million. The Firm's second quarter 2023 net income and diluted earnings per share compared to a net loss of $18.7 million and a loss per share of $1.03 for the second quarter 2022.

    For the six months ended June 30, 2023, revenues of $121.1 million compare to $81.5 million for the comparable period in 2022, an increase of $39.6 million. For the first half of 2023, a net loss of $18.9 million and a loss per share of $1.02 compare to a net loss of $30.8 million and a loss per share of $1.68 for the same period in 2022.

    The Firm's revenues and net income can fluctuate materially depending on the number, size and timing of completed transactions on which it advised and other factors. Accordingly, the revenues and net income in any particular period may not be indicative of future results.

    "The most important development in our business in recent months was the announcement of our agreement to be acquired by the U.S. subsidiary of Mizuho, the Japanese bank, and in the weeks since then we have made good progress toward completing that transaction. At the same time, our business has continued to perform well, with a respectable level of revenue relative to a very quiet M&A market, continued strong retention of employees, recruitment of new talent at all levels and a pace of new client assignment wins that is unchanged since our transaction announcement. We look forward to completing our transaction, after which we will seek to deliver to clients the best of two business models: a leading global advisory business operating under the familiar Greenhill brand along with the full suite of financing and other products that a major, full service, global investment bank like Mizuho can offer," Scott L. Bok, Chairman and Chief Executive Officer, commented.

    Revenues

    Revenues were $71.4 million in the second quarter of 2023 compared to $36.0 million in the second quarter of 2022, an increase of $35.4 million, or 98%. The improvement principally resulted from an increase in the number and size of transaction completion fees.

    For the six months ended June 30, 2023, revenues were $121.1 million compared to $81.5 million in 2022, an increase of $39.6 million, or 49%. The increase principally resulted from larger transaction completion fees and an increase in retainer fees. On a year to date basis our performance was stronger across all regions, and particularly strong in the U.S., as compared to the same year to date period in 2022.

    Recruiting Update

    Today we are announcing the recruitment of two new Managing Directors. Derek Deas (most recently Managing Director at Credit Suisse) will join our Houston office as a Managing Director focused on the Oil and Gas sector. Manish Nehra (most recently Managing Director at Credit Suisse) will join as a Managing Director focused on Industrials M&A, based in New York.

    Including all Managing Directors whose recruitment we have announced to date, we have 77 client-facing Managing Directors as of this date.

    Expenses

    Operating Expenses

    Our total operating expenses for the second quarter of 2023 were $56.6 million, which compared to $56.9 million of total operating expenses for the second quarter of 2022. The slight decrease in total operating expenses of $0.3 million resulted from a decrease in our compensation and benefits expenses offset by an increase in our non-compensation operating expenses, each as described in more detail below.

    For the six months ended June 30, 2023, our total operating expenses were $132.1 million, which compared to $116.9 million of total operating expenses in the first half of 2022. The increase in total operating expenses of $15.2 million, or 13%, resulted from increases in our compensation and benefits expenses and non-compensation operating expenses, each as described in more detail below.

    The following table sets forth information relating to our operating expenses.

     

     

    For the Three Months

    Ended June 30,

     

    For the Six Months

    Ended June 30,

     

    2023

     

    2022

     

    2023

     

    2022

     

    (in millions, unaudited)

     

    Employee compensation and benefits expenses

    $38.2

     

    $43.2

     

    $98.8

     

    $90.0

    % of revenues

    54%

     

    120%

     

    82%

     

    110%

    Non-compensation operating expenses

    18.4

     

    13.8

     

    33.3

     

    26.9

    % of revenues

    26%

     

    38%

     

    28%

     

    33%

    Total operating expenses

    56.6

     

    56.9

     

    132.1

     

    116.9

    % of revenues

    79%

     

    158%

     

    109%

     

    143%

    Total operating income (loss)

    14.8

     

    (20.9)

     

    (11.0)

     

    (35.4)

    Operating profit margin

    21%

     

    NM

     

    NM

     

    NM

     

    Compensation and Benefits Expenses

    Our employee compensation and benefits expenses for the second quarter of 2023 were $38.2 million as compared to $43.2 million for the second quarter of 2022. The decrease in expense of $5.0 million, or 11%, was largely due to a reduction in accrued compensation to better align compensation with year to date revenue generation and reduced amortization of deferred compensation due to higher forfeitures of unvested awards. The ratio of compensation expense to revenues declined to 54% in the second quarter of 2023 as compared to 120% in the same period in 2022 principally due to significantly higher revenues in the second quarter of 2023.

    For the six months ended June 30, 2023, our employee compensation and benefits expenses were $98.8 million compared to $90.0 million for the same period in 2022. The increase in expense of $8.8 million, or 10%, was largely a result of the timing of an accounting charge for incentive compensation. The ratio of compensation to revenues for the six month periods in 2023 declined to 82% for the six months ended June 30, 2023 as compared to 110% in the same period in 2022 principally due to much higher first half revenues in 2023.

    Our compensation expense is generally based upon revenues and can fluctuate materially in any particular period depending upon changes in headcount, amount of revenues recognized, as well as other factors. Accordingly, the amount of compensation expense recognized in any particular period may not be indicative of compensation expense in a future period.

    Non-Compensation Operating Expenses

    For the three months ended June 30, 2023, our non-compensation operating expenses of $18.4 million increased $4.6 million, or 34%, as compared to $13.8 million in the same period in 2022. The increase principally resulted from a foreign currency loss in the second quarter of 2023 compared to a foreign currency gain in the same period in the prior year, an increase in professional fees due to the pending Mizuho transaction, and higher information services costs.

    Non-compensation expenses as a percentage of revenues for the three months ended June 30, 2023 were 26% compared to 38% for the same period in 2022. The decrease in non-compensation expenses as a percentage of revenues resulted from the effect of spreading higher non-compensation costs over much higher revenues in the second quarter of 2023 as compared to the same period in 2022.

    For the first half of 2023, our non-compensation operating expenses of $33.3 million increased $6.4 million, or 24% as compared to $26.9 million in the comparable period in 2022. The increase principally resulted from incremental costs related to our relocation to new space in London, higher travel costs, professional fees incurred related to our acquisition, increased information services costs as well as the impact of foreign currency as mentioned above.

    Non-compensation expenses as a percentage of revenues for the six months ended June 30, 2023 were 28% compared to 33% for the same period in 2022. The decrease in non-compensation expenses as a percentage of revenues resulted from the effect of spreading higher non-compensation costs over much higher revenues in the six months ended June 30, 2023, as compared to the same period in 2022.

    Our non-compensation operating expenses can vary as a result of a variety of factors such as changes in headcount, the amount of recruiting and business development activity, the amount of office expansion, the amount of client reimbursed expenses, the impact of currency movements and other factors. Accordingly, the non-compensation operating expenses in any particular period may not be indicative of the non-compensation operating expenses in future periods.

    Interest Expense

    For the three months ended June 30, 2023, we incurred interest expense of $6.3 million as compared to $3.3 million for the same period in 2022. The increase of $3.0 million principally related to impact of significantly higher market borrowing rates in the second quarter of 2023 compared to the same period in 2022.

    For the six months ended June 30, 2023, we incurred interest expense of $12.1 million, an increase of $6.1 million as compared to $6.0 million for the same period in 2022. The increase principally related to the impact of significantly higher market borrowing rates in the first six months of 2023 as compared to the same period in 2022.

    The rate of interest on our borrowing is based on LIBOR and can vary from period to period. Accordingly, the amount of interest expense in any particular period may not be indicative of the amount of interest expense in future periods. There can be no certainty that our borrowing rate will not increase in future periods as a result of the transition from LIBOR to SOFR or another alternative rate.

    Provision for Income Taxes

    For the three months ended June 30, 2023, we recognized income tax expense of $4.1 million, which reflected an effective tax rate of 48%. This compared to an income tax benefit of $5.4 million for the same period in 2022, which reflected an effective tax rate of 22%. The income tax expense for the quarter ended June 30, 2023 included a charge of $1.9 million related to the tax effect of the vesting of restricted stock units with a grant price higher than the market price. Excluding this charge, the effective tax rate for the second quarter of 2023 would have been 27%.

    For the six months ended June 30, 2023, due to our pre-tax loss we recognized an income tax benefit of $4.2 million, which included a charge of $1.8 million related to the tax effect of the vesting of restricted stock units at a grant price higher than the market price. This compared to an income tax benefit for the six month period ended June 30, 2022 of $10.6 million, which included a benefit of $1.0 million related to the tax effect of the vesting of restricted stock units at a market price higher than the grant price. Excluding these charges/benefits, the effective tax rates for the six month periods ended June 30, 2023 and 2022 would have been 26% and 23%, respectively.

    The effective tax rate can fluctuate as a result of variations in the relative amounts of income earned and the tax rate imposed in the tax jurisdictions in which we operate. Accordingly, the effective tax rate in any particular period may not be indicative of the effective tax rate in future periods.

    Liquidity and Capital Resources

    As of June 30, 2023, we had cash and cash equivalents of $47.7 million and term loan debt with a principal balance of $270.1 million. Our net debt was $222.4 million. The remaining principal balance of the term loan is due at maturity on April 12, 2024 and may be repaid further in advance of maturity without penalty.

    During the second quarter of 2023, we repurchased 401,485 restricted stock units from employees at the time of vesting to settle tax liabilities at an average price of $6.96 per share, for a total cost of $2.8 million.

    In the aggregate for the year, as of June 30, 2023, we have repurchased in the open market 69,112 shares of our common stock at an average price of $11.88 per share, for a total cost of $0.8 million and also repurchased 909,722 restricted stock units from employees at the time of vesting to settle withholding tax liabilities at an average price of $10.81 per share, for a total cost of $9.8 million.

    For the twelve month period through January 31, 2024, our Board of Directors has authorized up to $30 million in purchases of shares and share equivalents (via tax withholding on vesting of restricted stock units). As of June 30, 2023, we have $19.9 million remaining under that authorization.

    Under the terms of the merger agreement with Mizuho, Mizuho has agreed to (i) refinance our term loan if the proposed transaction has not closed by March 12, 2024 on the terms specified in the merger agreement, and (ii) if at the time of closing of the proposed transaction, our credit agreement is outstanding and our term loan has not been refinanced by Mizuho, to repay in full all obligations of the term loan on the terms specified in the merger agreement.

    Pending Merger with Mizuho

    On May 22, 2023, we and Mizuho Financial Group, Inc. announced that we entered into a definitive agreement under which Mizuho will acquire Greenhill in an all-cash transaction at $15 per share. Under the terms of the merger agreement, which was unanimously approved by our Board of Directors, a wholly owned subsidiary of Mizuho Americas, LLC will merge with and into Greenhill, with Greenhill surviving the merger as a wholly owned subsidiary of Mizuho Americas, LLC. The transaction is expected to close by year end and is subject to approval by Greenhill stockholders, as well as required regulatory approvals and other customary closing conditions. As a result of the proposed transaction with Mizuho, Greenhill will not be hosting a conference call related to its second quarter 2023 earnings release.

    Dividend

    The Board of Directors of Greenhill & Co., Inc. has declared a dividend of $0.10 per share to be paid on September 27, 2023 to common stockholders of record on September 13, 2023.

    Greenhill & Co., Inc. is a leading independent investment bank entirely focused on providing financial advice on significant mergers, acquisitions, restructurings, financings and capital raising to corporations, partnerships, institutions and governments globally. It acts for clients located throughout the world from its offices in New York, Chicago, Frankfurt, Hong Kong, Houston, London, Madrid, Melbourne, Paris, San Francisco, Singapore, Stockholm, Sydney, Tokyo and Toronto.

    Cautionary Note Regarding Forward-Looking Statements

    The preceding discussion should be read in conjunction with our condensed consolidated financial statements and the related notes that appear below. We have made statements in this discussion that are forward-looking statements. Words or phrases such as "believe," "estimate," "expect," "anticipate," "plan," "trend," "objective," "continue," or similar expressions or future or conditional verbs such as "will," "would," "should," "could," "might," "may," or similar expressions, or the negatives of those words or phrases, may identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, assumptions, estimates, and other important factors that change over time and could cause actual results to differ materially from any results, performance, or events expressed or implied by such forward-looking statements. Such forward-looking statements include but are not limited to statements about the benefits of the proposed acquisition of Greenhill by Mizuho, including future financial and operating results, Greenhill's or Mizuho's plans, objectives, expectations and intentions, the expected timing of completion of the proposed transaction and other statements that are not historical facts.

    These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. In addition to factors previously disclosed in our reports filed with the Securities and Exchange Commission (the "SEC") and those identified elsewhere in this communication, the following factors, among others, could cause actual results to differ materially from forward-looking statements or historical performance: the occurrence of any event, change, or other circumstance that could give rise to the right of Greenhill or Mizuho to terminate the definitive merger agreement; the outcome of any legal proceedings that may be instituted against us or Mizuho; the possibility that the proposed transaction does not close when expected or at all because required regulatory, stockholder, or other approvals and other conditions to closing are not received or satisfied on a timely basis or at all (and the risk that such approvals may result in the imposition of conditions that could adversely affect us or Mizuho or the expected benefits of the proposed transaction); the risk that the benefits from the proposed transaction may not be fully realized or may take longer to realize than expected, including as a result of changes in, or problems arising from, general economic, political and market conditions, interest and exchange rates, laws and regulations and their enforcement, and the degree of competition in the geographic and business areas in which we and Mizuho operate; the ability to promptly and effectively integrate the businesses of Greenhill with those of Mizuho; the possibility that the proposed transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; reputational risk and potential adverse reactions of the our or Mizuho's clients, employees or other business partners, including those resulting from the announcement or completion of the proposed transaction; the diversion of management's attention and time from ongoing business operations and opportunities on merger-related matters; and the impact of the global COVID-19 pandemic on our or Mizuho's businesses, the ability to complete the proposed transaction or any of the other foregoing risks.

    These factors are not necessarily all of the factors that could cause our or Mizuho's actual results, performance, or achievements to differ materially from those expressed in or implied by any of the forward-looking statements. Other unknown or unpredictable factors also could harm our or Mizuho's results.

    All forward-looking statements attributable to us or Mizuho, or persons acting on our or Mizuho's behalf, are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made and we and Mizuho do not undertake or assume any obligation to update publicly any of these statements to reflect actual results, new information or future events, changes in assumptions, or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we or Mizuho update one or more forward-looking statements, no inference should be drawn that we or Mizuho will make additional updates with respect to those or other forward-looking statements. Further information regarding Greenhill and factors which could affect the forward-looking statements contained herein can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and our other filings with the SEC. Further information regarding factors that could affect Mizuho's results is included in a number of publicly available documents published by Mizuho. These include Mizuho's annual securities report, Integrated Report, and "Item 3.D. Key Information-Risk Factors" in Mizuho's most recent Form 20-F filed with the SEC, which is available in the Financial Information section of Mizuho's web page at www.mizuhogroup.com and also at the SEC's web site at www.sec.gov.

    Additional Information and Where to Find It

    In connection with the proposed transaction, we filed with the SEC a definitive proxy statement on July 13, 2023, which was mailed to Greenhill stockholders on or about July 14, 2023. This communication does not constitute a solicitation of any vote or approval. GREENHILL STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT GREENHILL, MIZUHO, AND THE PROPOSED TRANSACTION. Investors will be able to obtain a free copy of documents filed with the SEC at the SEC's website at http://www.sec.gov. In addition, investors may obtain a free copy of our filings with the SEC from the investors relations section of our website at https://www.greenhill.com/en/investor/filings or by directing a request to: Greenhill & Co., Inc., 1271 Avenue of the Americas, New York, NY 10020, (212) 389-1800, [email protected].

    Participants in the Solicitation

    Greenhill, its directors and certain of its officers and employees may be deemed to be participants in the solicitation of proxies from Greenhill stockholders in connection with the proposed transaction. Information about the interests of our directors and executive officers and other persons who may be deemed to be participants in the solicitation of Greenhill stockholders in connection with the proposed transaction and a description of their direct and indirect interests, by security holdings or otherwise, are included in the definitive proxy statement related to the proposed transaction, which was filed with the SEC on July 13, 2023 and mailed to Greenhill stockholders on or about July 14, 2023. Additional information about Greenhill, our directors and executive officers and their ownership of Greenhill common stock is also set forth in the definitive proxy statement for our 2023 Annual Meeting of Stockholders, as filed with the SEC on Schedule 14A on March 13, 2023, and other documents subsequently filed by us with the SEC. Free copies of these documents may be obtained as described above.

     

    Greenhill & Co., Inc. and Subsidiaries

    Condensed Consolidated Statements of Operations (Unaudited)

    (In thousands, except share and per share data)

     

     

    For the Three Months

    Ended June 30,

     

    For the Six Months

    Ended June 30,

     

     

    2023

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Revenues

    $

    71,435

     

    $

    36,049

     

     

    $

    121,113

     

     

    $

    81,490

     

     

     

     

     

     

     

     

     

    Operating Expenses

     

     

     

     

     

     

     

    Employee compensation and benefits

     

    38,223

     

     

    43,163

     

     

     

    98,799

     

     

     

    90,012

     

    Occupancy and equipment rental

     

    4,732

     

     

    4,439

     

     

     

    9,721

     

     

     

    8,842

     

    Depreciation and amortization

     

    886

     

     

    625

     

     

     

    1,773

     

     

     

    1,245

     

    Information services

     

    3,421

     

     

    2,336

     

     

     

    5,777

     

     

     

    4,636

     

    Professional fees

     

    2,987

     

     

    2,231

     

     

     

    4,982

     

     

     

    4,197

     

    Travel related expenses

     

    1,676

     

     

    1,549

     

     

     

    3,599

     

     

     

    2,669

     

    Other operating expenses

     

    4,689

     

     

    2,579

     

     

     

    7,460

     

     

     

    5,290

     

    Total operating expenses

     

    56,614

     

     

    56,922

     

     

     

    132,111

     

     

     

    116,891

     

    Total operating income (loss)

     

    14,821

     

     

    (20,873

    )

     

     

    (10,998

    )

     

     

    (35,401

    )

    Interest expense

     

    6,260

     

     

    3,258

     

     

     

    12,073

     

     

     

    6,013

     

    Income (loss) before taxes

     

    8,561

     

     

    (24,131

    )

     

     

    (23,071

    )

     

     

    (41,414

    )

    Provision (benefit) for taxes

     

    4,124

     

     

    (5,399

    )

     

     

    (4,190

    )

     

     

    (10,576

    )

    Net income (loss)

    $

    4,437

     

    $

    (18,732

    )

     

    $

    (18,881

    )

     

    $

    (30,838

    )

     

     

     

     

     

     

     

     

    Average shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    18,802,352

     

     

    18,237,538

     

     

     

    18,560,137

     

     

     

    18,330,545

     

    Diluted

     

    21,461,523

     

     

    18,237,538

     

     

     

    18,560,137

     

     

     

    18,330,545

     

    Earnings (loss) per share:

     

     

     

     

     

     

     

    Basic

    $

    0.24

     

    $

    (1.03

    )

     

    $

    (1.02

    )

     

    $

    (1.68

    )

    Diluted

    $

    0.21

     

    $

    (1.03

    )

     

    $

    (1.02

    )

     

    $

    (1.68

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230809232249/en/

    Get the next $GHL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GHL

    DatePrice TargetRatingAnalyst
    4/28/2022$16.50 → $12.00Mkt Perform → Underperform
    Keefe Bruyette
    3/9/2022$18.50 → $17.00Neutral
    Piper Sandler
    7/14/2021$15.50Underperform → Market Perform
    Keefe, Bruyette & Woods
    More analyst ratings

    $GHL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Greenhill downgraded by Keefe Bruyette with a new price target

      Keefe Bruyette downgraded Greenhill from Mkt Perform to Underperform and set a new price target of $12.00 from $16.50 previously

      4/28/22 6:12:12 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Piper Sandler reiterated coverage on Greenhill & Co with a new price target

      Piper Sandler reiterated coverage of Greenhill & Co with a rating of Neutral and set a new price target of $17.00 from $18.50 previously

      3/9/22 6:45:52 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Greenhill & Co upgraded by Keefe, Bruyette & Woods with a new price target

      Keefe, Bruyette & Woods upgraded Greenhill & Co from Underperform to Market Perform and set a new price target of $15.50

      7/14/21 5:05:57 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance

    $GHL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Land & Buildings Nominates Two Independent Candidates – Jim Hoffmann and Adam Troso – for Board of National Health Investors

      Believes That Incremental Changes Since Last Annual Meeting Are Insufficient to Address the Poor Corporate Governance and Concerning Conflicts of Interest Threatening to Prevent NHI From Reaching its Full Value Potential Highlights the Urgent Need for NHI to Have Truly Independent Directors With the Right Expertise in the Boardroom Given Ongoing Lease Renewal Negotiations With Major Tenant National Healthcare Corp (NHC) Details Concerns That NHC Lease Negotiations Will Not Reflect Market Value Given Board Member Conflicts; Lease Likely Has 75% Upside Based on Strong Coverage and Precedent Transactions and Could Boost Earnings 13% Or More Believes NHI Shares Have 50% Upside Over the Next

      2/19/25 8:00:00 AM ET
      $DOC
      $GHL
      $HCP
      $ING
      Real Estate Investment Trusts
      Real Estate
      Investment Bankers/Brokers/Service
      Finance
    • Greenhill & Co. Reports Second Quarter 2023 Results

      Announced definitive agreement for Greenhill to be acquired by Mizuho Financial Group, Inc. in an all-cash transaction at $15 per share Quarterly revenues of $71.4 million, up 98% from prior year's second quarter Year to date revenues of $121.1 million, up 49% from the same period in 2022 Compensation ratio of 54% for the quarter; 82% for the year to date period Operating margin of 21% for the quarter Recruited two additional Managing Directors during the quarter Greenhill & Co., Inc. (NYSE:GHL) today reported revenues of $71.4 million, net income of $4.4 million and diluted earnings per share of $0.21 for the quarter ended June 30, 2023. The Firm's second quarter

      8/9/23 4:05:00 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE, and VECT

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

      6/3/23 8:17:00 PM ET
      $CWBR
      $GHL
      $PDCE
      $VECT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Investment Bankers/Brokers/Service
      Finance

    $GHL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ferro Kevin returned 81,495 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - GREENHILL & CO INC (0001282977) (Issuer)

      12/1/23 9:08:03 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Wyles David returned 98,707 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - GREENHILL & CO INC (0001282977) (Issuer)

      12/1/23 9:05:56 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Ekman Ulrika returned 10,205 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - GREENHILL & CO INC (0001282977) (Issuer)

      12/1/23 9:03:36 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance

    $GHL
    SEC Filings

    See more
    • SEC Form 15-12G filed by Greenhill & Co. Inc.

      15-12G - GREENHILL & CO INC (0001282977) (Filer)

      12/11/23 4:03:05 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form S-8 POS filed by Greenhill & Co. Inc.

      S-8 POS - GREENHILL & CO INC (0001282977) (Filer)

      12/1/23 8:44:25 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form S-8 POS filed by Greenhill & Co. Inc.

      S-8 POS - GREENHILL & CO INC (0001282977) (Filer)

      12/1/23 8:41:52 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance

    $GHL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Greenhill & Co. Inc. (Amendment)

      SC 13G/A - GREENHILL & CO INC (0001282977) (Subject)

      7/17/23 4:18:36 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form SC 13D/A filed by Greenhill & Co. Inc. (Amendment)

      SC 13D/A - GREENHILL & CO INC (0001282977) (Subject)

      5/22/23 5:28:29 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form SC 13G/A filed by Greenhill & Co. Inc. (Amendment)

      SC 13G/A - GREENHILL & CO INC (0001282977) (Subject)

      1/9/23 11:41:53 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance

    $GHL
    Financials

    Live finance-specific insights

    See more
    • Land & Buildings Nominates Two Independent Candidates – Jim Hoffmann and Adam Troso – for Board of National Health Investors

      Believes That Incremental Changes Since Last Annual Meeting Are Insufficient to Address the Poor Corporate Governance and Concerning Conflicts of Interest Threatening to Prevent NHI From Reaching its Full Value Potential Highlights the Urgent Need for NHI to Have Truly Independent Directors With the Right Expertise in the Boardroom Given Ongoing Lease Renewal Negotiations With Major Tenant National Healthcare Corp (NHC) Details Concerns That NHC Lease Negotiations Will Not Reflect Market Value Given Board Member Conflicts; Lease Likely Has 75% Upside Based on Strong Coverage and Precedent Transactions and Could Boost Earnings 13% Or More Believes NHI Shares Have 50% Upside Over the Next

      2/19/25 8:00:00 AM ET
      $DOC
      $GHL
      $HCP
      $ING
      Real Estate Investment Trusts
      Real Estate
      Investment Bankers/Brokers/Service
      Finance
    • Greenhill & Co. Reports Second Quarter 2023 Results

      Announced definitive agreement for Greenhill to be acquired by Mizuho Financial Group, Inc. in an all-cash transaction at $15 per share Quarterly revenues of $71.4 million, up 98% from prior year's second quarter Year to date revenues of $121.1 million, up 49% from the same period in 2022 Compensation ratio of 54% for the quarter; 82% for the year to date period Operating margin of 21% for the quarter Recruited two additional Managing Directors during the quarter Greenhill & Co., Inc. (NYSE:GHL) today reported revenues of $71.4 million, net income of $4.4 million and diluted earnings per share of $0.21 for the quarter ended June 30, 2023. The Firm's second quarter

      8/9/23 4:05:00 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE, and VECT

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

      6/3/23 8:17:00 PM ET
      $CWBR
      $GHL
      $PDCE
      $VECT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Investment Bankers/Brokers/Service
      Finance